

REMARKS

Claims 27-39 have been canceled without prejudice or disclaimer. Claims 40-86 have been added and therefore are pending in the present application. Claims 40-86 are supported throughout the specification, including the original claims.

Applicants submit herewith a substitute Sequence Listing in the form of a text file. The text file acts as both the paper copy and the computer readable form of the Sequence Listing. The specification has been amended to identify the sequences disclosed therein.

It is respectfully submitted that the present amendment presents no new issues or new matter and places this case in condition for allowance. Reconsideration of the application in view of the above amendments and the following remarks is requested.

I. The Objection to the Specification

The Office objected to the disclosure due to informalities. First, the Office objected to the amino acid sequence of SEQ ID NO: 1 because X₅ (position 7) is defined to be R, K, W or G at page 1 but the amino acid K is not included in SEQ ID NO: 1 in the sequence listing. The substitute sequence listing includes lysine in the definition of X₅ (position 7) of SEQ ID NO: 1.

Second, the Office stated that the specification recites sequences without providing sequence identifiers. The specification has been amended to include sequence identifiers for each sequence.

For the foregoing reasons, Applicants submit that the specification overcomes this objection. Applicants respectfully request reconsideration and withdrawal of the objection.

II. The Rejection of Claims 40-79 under 35 U.S.C. 112

Claims 40-79 are rejected under 35 U.S.C. 112 as being indefinite. Specifically, the Office Action stated that the amino acid sequence of SEQ ID NO: 1 recited in claim 40 is different from SEQ ID NO: 1 in the sequence listing because X₅ (position 7) is defined to be R, K, W or G at page 1 whereas the amino acid K is not included in SEQ ID NO: 1 in the sequence listing.

As stated above, the substitute sequence listing includes lysine in the definition of X₅ (position 7) of SEQ ID NO: 1. Applicants therefore submit that this rejection has been overcome.

III. Conclusion

In view of the above, it is respectfully submitted that all claims are in condition for allowance. Early action to that end is respectfully requested. The Examiner is hereby invited to

contact the undersigned by telephone if there are any questions concerning this amendment or application.

All required fees were charged to Novozymes North America, Inc.'s Deposit Account No. 50-1701 at the time of electronic filing. The USPTO is authorized to charge this Deposit Account should any additional fees be due.

Respectfully submitted,

Date: April 19, 2010

/Elias Lambiris, Reg. # 33728/
Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097